The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on ≥ 1 line of endocrine therapy: systematic review and meta-analysis.

BMC Cancer · 2024 · PMC10763362 · PMID 38166684

Europe PMC DOI

hedged sentence

0.0300

closest p · 0.6× alpha

0.0300

boldest claim

The sentences

showed a trendp = 0.03actually significant

In addition, patients with ESR1m showed a trend of OS improvement in Elacestrant (HR = 0.59; p = 0.03).

also in 23,610 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.